D Liénard

2.6k total citations · 2 hit papers
20 papers, 2.1k citations indexed

About

D Liénard is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, D Liénard has authored 20 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Oncology and 7 papers in Immunology. Recurrent topics in D Liénard's work include Immunotherapy and Immune Responses (7 papers), Cutaneous Melanoma Detection and Management (7 papers) and T-cell and B-cell Immunology (5 papers). D Liénard is often cited by papers focused on Immunotherapy and Immune Responses (7 papers), Cutaneous Melanoma Detection and Management (7 papers) and T-cell and B-cell Immunology (5 papers). D Liénard collaborates with scholars based in Switzerland, Belgium and Netherlands. D Liénard's co-authors include Patricia Ewalenko, Ferdy J. Lejeune, Donata Rimoldi, Nathalie Renard, J C Cerottini, Pedro Romero, Lars E. French, Pascal Schneider, J Tschopp and Michael Hahne and has published in prestigious journals such as Science, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

D Liénard

20 papers receiving 2.1k citations

Hit Papers

Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Impli... 1992 2026 2003 2014 1996 1992 250 500 750 1000

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D Liénard Switzerland 13 1.1k 978 861 263 214 20 2.1k
Mariella Parenza Italy 21 1.4k 1.3× 757 0.8× 758 0.9× 265 1.0× 339 1.6× 27 2.2k
Keren Coplan United States 21 1.3k 1.2× 1.1k 1.2× 1.2k 1.4× 435 1.7× 163 0.8× 25 2.6k
Luca Sigalotti Italy 28 1.1k 1.0× 1.7k 1.7× 813 0.9× 207 0.8× 140 0.7× 61 2.6k
Antoinette Hatzfeld France 27 551 0.5× 1.1k 1.1× 446 0.5× 205 0.8× 176 0.8× 74 2.2k
Steven C. Ziesmer United States 35 1.5k 1.4× 580 0.6× 1.2k 1.4× 197 0.7× 115 0.5× 65 3.2k
José A. García‐Marco Spain 29 798 0.7× 816 0.8× 589 0.7× 170 0.6× 94 0.4× 88 2.6k
Camille N. Abboud United States 27 558 0.5× 810 0.8× 783 0.9× 261 1.0× 178 0.8× 109 2.7k
Julie S. Nielsen Canada 20 959 0.9× 686 0.7× 927 1.1× 139 0.5× 137 0.6× 26 2.0k
Ajay K. Malik United States 10 437 0.4× 1.1k 1.2× 590 0.7× 152 0.6× 161 0.8× 16 1.8k
John C. Cawley United Kingdom 36 1.7k 1.6× 1.2k 1.2× 702 0.8× 166 0.6× 176 0.8× 135 3.8k

Countries citing papers authored by D Liénard

Since Specialization
Citations

This map shows the geographic impact of D Liénard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D Liénard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D Liénard more than expected).

Fields of papers citing papers by D Liénard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D Liénard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D Liénard. The network helps show where D Liénard may publish in the future.

Co-authorship network of co-authors of D Liénard

This figure shows the co-authorship network connecting the top 25 collaborators of D Liénard. A scholar is included among the top collaborators of D Liénard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D Liénard. D Liénard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cherix, Stéphane, Maurice Matter, Wassim Raffoul, et al.. (2008). Isolated limb perfusion with tumor necrosis factor and melphalan for non‐resectable soft tissue sarcomas: Long‐term results on efficacy and limb salvage in a selected group of patients. Journal of Surgical Oncology. 98(3). 148–155. 37 indexed citations
2.
Matter, Maurice, Marie Nicod Lalonde, Ariane Boubaker, et al.. (2007). The Role of Interval Nodes in Sentinel Lymph Node Mapping and Dissection for Melanoma Patients. Journal of Nuclear Medicine. 48(10). 1607–1613. 21 indexed citations
4.
Posner, Marshall, et al.. (2006). Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.. PubMed. 1(4). 274–80. 11 indexed citations
5.
Eggermont, A.M.M., Stefan Suciu, W. Ruka, et al.. (2004). 25 Update of EORTC melanoma trials. Final results of the EORTC melanoma group trials: EORTC 18951 in stage IV and EORTC 18952 in stage IIB–III. Melanoma Research. 14(4). A11–A12. 1 indexed citations
7.
Valmori, Danila, Valérie Dutoit, Verena Rubio‐Godoy, et al.. (2001). Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma.. PubMed. 61(2). 509–12. 65 indexed citations
8.
Romero, Pedro, Danila Valmori, Daniel E. Speiser, et al.. (2000). Immune Monitoring in Cancer Immunotherapy. PubMed. 75–97. 5 indexed citations
9.
Valmori, Danila, Mikäel J. Pittet, Cédric Vonarbourg, et al.. (1999). Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376.. PubMed. 59(16). 4050–5. 63 indexed citations
10.
Eggermont, A.M.M., et al.. (1997). Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.. PubMed. 24(5). 547–55. 28 indexed citations
11.
Valmori, Danila, D Liénard, Gary A. Waanders, et al.. (1997). Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.. PubMed. 57(4). 735–41. 52 indexed citations
12.
Lejeune, Ferdy J., et al.. (1997). Treatment of in-transit melanoma metastases with tumour necrosis factor (TNF-??) and chemotherapy administered in isolated limb perfusion (ILP). Melanoma Research. 7(Supplement 1). S48–S48. 2 indexed citations
13.
Hahne, Michael, Donata Rimoldi, Michael Schröter, et al.. (1996). Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape. Science. 274(5291). 1363–1366. 1052 indexed citations breakdown →
14.
Lejeune, F., D Liénard, A.M.M. Eggermont, et al.. (1995). Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results.. PubMed. 5(2). 73–81. 20 indexed citations
15.
Lejeune, F., D Liénard, A Eggermont, et al.. (1994). Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma.. PubMed. 43(4). 191–7. 37 indexed citations
16.
Liénard, D, et al.. (1994). Physiological and pharmacokinetics parameters in isolation perfusion of the limbs.. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 241–248. 2 indexed citations
18.
Liénard, D, et al.. (1992). High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.. Journal of Clinical Oncology. 10(1). 52–60. 571 indexed citations breakdown →
19.
Lejeune, Ferdinand, et al.. (1989). Assessment of the haematocrit method for dosimetry of cytostatics in isolation perfusion. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 2. 82–86. 7 indexed citations
20.
Lejeune, Ferdinand, et al.. (1989). Results of 206 isolated limb perfusions for malignant melanoma.. PubMed. 15(6). 510–9. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026